Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
- Conditions
- Interventions
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 1011
- Registration Number
- NCT02317198
- Locations
- 🇳🇱
St. Antonius hospital, Nieuwegein, Utrecht, Netherlands
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Hospital do Coracao
- Target Recruit Count
- 3799
- Registration Number
- NCT02298088
- Locations
- 🇦🇷
Hospital Alvarez, Ciudad Autonoma de Buenos Aires, Argentina
🇵🇪Hospital Cayetano Heredia, Lima, Peru
🇷🇺State Healthcare Institution "Belgorod regional clinical hospital named after Prelate Ioasaf, Belgorod, Russian Federation
Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT02294643
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3037
- Registration Number
- NCT02293395
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 87
- Registration Number
- NCT02287909
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
High "on Treatment" Platelet Reactivity in the Intensive Care Unit
- Conditions
- Interventions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 200
- Registration Number
- NCT02285751
- Locations
- 🇦🇹
General Hospital, Vienna, Austria
Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02265289
Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02262650
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
- Conditions
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 600
- Registration Number
- NCT02233790
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 46
- Registration Number
- NCT02230527
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.